Lee BottomleyWest Midlands
Edmund DoyleA man has cycled solo from Cheshire to China to raise funds for a mental health charity.
Edmund Doyle, from…
Author: admin
-
Crewe cyclist completes solo ride to China for charity
Edmund DoyleEdmund Doyle took on the challenge to help men’s mental health services after his own struggles -
Sandwich and cake shop set up in memory of Shrewsbury crash death teenager
“When you lose a child you just have to try and find some sort of hope and give yourself something to focus on,” she said.
The shop had been an idea for a while, she explained, because her son “had dreams of one day opening a little deli in town”.
It will support a charity she is in the process of registering called Shine on with Harvey.
Ms Owen said her son “just had a such a soft spot for anybody who was disadvantaged,” so she wanted to do something for other young people.
As well as donating money to a couple of local arts groups, the charity has paid for pottery classes, barbeque lessons, glass painting and art classes.
She said it aimed to give “disadvantaged young people to access music and creative activities, helping them build skills and confidence”.
Once Crystal’s Shine on Bakery becomes profitable, it will pass on money to the charity, including money raised through a monthly cake raffle.
It will also have information about the charity and how people could donate.
Continue Reading
-
Browser agents don’t always respect your privacy choices
Browser agents promise to handle online tasks without constant user input. They can shop, book reservations, and manage accounts by driving a web browser through an AI model. A new academic study warns that this convenience comes with…
Continue Reading
-
Stardust Study Redefines Spread of Life’s Atoms
Starlight and stardust are not enough to drive the powerful winds of giant stars, transporting the building blocks of life through our galaxy. That’s the conclusion of a new study from Chalmers University of Technology, Sweden, of red…
Continue Reading
-
Parents urged to trust their instincts over childhood cancer
The You Know Them Best campaign aims to primarily raise awareness among families across the West Midlands, Gloucestershire, Worcestershire and Herefordshire. To date the trust has supported more than 500 families in these areas.
Founded in memory…
Continue Reading
-
MSF's vital humanitarian activities in Gaza at risk from Israeli registration rules – ReliefWeb
- MSF’s vital humanitarian activities in Gaza at risk from Israeli registration rules ReliefWeb
- Why are Gaza’s war-damaged homes collapsing in winter? Al Jazeera
- 18 Palestinians killed in Gaza building collapses since ceasefire began TRT World
Continue Reading
-
Shionogi Receives Approval in Japan to Manufacture and Market ZURZUVAE® Capsules 30 mg for the Treatment of Major Depressive Disorder｜ SHIONOGI
OSAKA, Japan, December 22, 2025 – Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) is pleased to announce that it has obtained manufacturing and marketing approval in Japan for “ZURZUVAE® Capsules 30 mg” (non-proprietary name: zuranolone; hereafter “ZURZUVAE”) as of [December 22, 2025], for the indication of depression and depressive state.
The approval of ZURZUVAE is based on positive results from a Phase 3 randomized placebo-controlled clinical trial of Japanese adults with major depressive disorder conducted in Japan1. In this study, Oral administration of ZURZUVAE at 30 mg once daily for 14 consecutive days demonstrated efficacy and safety, showing rapid onset of symptom improvement from the early stages of treatment. Furthermore, efficacy and safety were confirmed even upon re-administration after a drug-free interval of six weeks or longer. The primary endpoint was the change from baseline in the HAM-D17 total score at the end of the 14-day treatment period. The treatment group showed a mean change of -7.43, which was statistically significantly greater than the placebo group (-6.23), with a least-squares mean difference of -1.20 (95% CI, -2.32 to -0.08; p < 0.0365). Based on these favorable results, ZURZUVAE has now been approved in Japan.
Depression affects an estimated 5 million people in Japan, representing one of the most burdensome non-fatal diseases in terms of social and health impact2. Conventional antidepressants often require several weeks to achieve therapeutic effect3, creating an unmet need for treatments with rapid onset4. ZURZUVAE is expected to address significant unmet needs in the field of depression by providing timely symptom relief for patients in need of therapeutic intervention.
Shionogi has identified “Contributing to a healthy and prosperous life” as a key materiality and is committed to building a society where everyone can live longer, healthier, and more fulfilling lives in their own way. We will continue striving to deliver this medicine—potentially capable of transforming the paradigm of depression treatment—to patients as quickly as possible.
About zuranolone (ZURZUVAE®)
Zuranolone is a novel oral antidepressant with a mechanism of action different from conventional therapies. It acts as a GABA-A receptor positive allosteric modulator (PAM) at both synaptic and extrasynaptic sites. Based on clinical trial results conducted by Shionogi, Oral administration of 30 mg once a day for 14 days has been shown to rapidly improve symptoms of major depressive disorder (MDD) without the need for dose adjustment.About Shionogi
Shionogi & Co., Ltd. is a leading global research-driven pharmaceutical company dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and well-being of the patients we serve.” Shionogi has discovered and developed novel antibiotics, medicines for HIV and influenza and currently markets medicines for infectious diseases and central nervous system disorders. Shionogi’s global pipeline includes research programs in infectious disease, pain/CNS, metabolic disorders, rare disease, oncology and stroke.
References
1. Psychiatry Clin Neurosci.2025 Nov 18.doi: 10.1111/pcn.13917.
2. WHO, Depression and Other Common Mental Disorders Global Health Estimates
3. Japanese Society of Mood Disorders Treatment Guidelines
4. Watanabe, Koichiro et al. Clinical Psychopharmacology. 2008; 11(12): 2295-2304.
For Further Information, Contact:
SHIONOGI Website Inquiry Form: https://www.shionogi.com/global/en/contact.html
Forward-Looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Continue Reading
-
Afghanistan: Weekly Market Report: Issue 276: Week 3 – December 2025 – ReliefWeb
- Afghanistan: Weekly Market Report: Issue 276: Week 3 – December 2025 ReliefWeb
- Food Prices Surge in Parwan Amid Continued Closure of Trade Passages with Pakistan خبرگزاری اطلس
- Imported fruit prices rise in Herat after Pakistan…
Continue Reading
-
Pharmacy urges ‘use right NHS service’ as pressure on A&E mounts
Bea SwallowWest of England
NHS EnglandCommunity pharmacist Ade Williams says pharmacies can act as a “gateway” to getting you the right care on the NHS People in the West of England are being reminded to avoid unnecessary trips to A&E after…
Continue Reading